Opthea

Opthea Ltd. is a clinical stage biopharmaceutical company that engages in the development of biological therapeutics for the treatment of progressive retinal diseases. It focuses on treating neovascular age-related macular degeneration and diabetic macular edema, which causes visual impairment among elderly and diabetic patients. The company was founded on October 17, 1984 and is headquartered in South Yarra, Australia.

Opthea Ltd. is a clinical stage biopharmaceutical company, which engages in the development of biological therapeutics for the treatment of progressive retinal diseases. It focuses on treating neovascular age-related macular degeneration and diabetic macular edema, which causes visual impairment among elderly and diabetic patients. The company was founded on October 17, 1984, and is headquartered in South Yarra, Australia.

MELBOURNE, Australia, March 05, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT; “Opthea”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, today announced that management will participate in one-on-one investor meetings at the Leerink Partners Global Biopharma Conference being held in Miami, Florida on March 11-13, 2024.

Opthea to Participate in the Leerink Partners Global Biopharma Conference

Enrollment completion of sozinibercept Phase 3 program for wet AMD expected in calendar year (CY) Q2 2024 with top-line data mid-CY 2025

Opthea Reports Half-Year Financial Results and Business Updates

Global retina expert joins to support sozinibercept development and launch preparation Global retina expert joins to support sozinibercept development and launch preparation

Opthea Appoints Arshad M. Khanani, MD, MA, FASRS, as Chief Medical Advisor

COAST trial is evaluating the superiority of sozinibercept combined with EYLEA ® (aflibercept) over EYLEA alone in wet AMD

Opthea Completes Enrollment in First Pivotal Trial with Sozinibercept

Dr. Julie Clark, SVP Clinical Development; Dr. Fang Li, SVP Regulatory Affairs, to join February 1stExperienced executives bring extensive track record in products for retinal and ophthalmology diseases

Opthea Strengthens Team with Key Clinical and Regulatory Hires

MELBOURNE, Australia, Dec. 27, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, today announced that it expects to receive the remaining US$35 million committed funds under the Development Funding Agreement (DFA) with Carlyle and Abingworth, and has entered into binding documentation with a new co-investor under an Amended DFA to secure an additional US$50 million in funding.

Opthea to Receive US$35M Commitment and Additional US$50M Funding

MELBOURNE, Australia, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; Nasdaq:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today that it has received an A$8.8 million (US$5.9 million) research and development (R&D) tax credit from the Australian Taxation Office. The cash incentive is for research and development costs incurred in the 2022/2023 financial year, and represents the amount disclosed in the company's audited financial statements at 30 June 2023.

Opthea Receives A$8.8 million R&D Tax Incentive

MELBOURNE, Australia, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, today announced an oral presentation featuring sozinibercept (OPT-302) which will be presented at the annual FLORetina Congress being held November 30 to December 3, 2023, in Rome, Italy.

Opthea to Present at the FLORetina 2023 Congress

MELBOURNE, Australia, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today that Dr. Megan Baldwin, the Company's Founder and Chief Innovation Officer, will participate in a fireside chat at the Jefferies London Healthcare Conference being held on November 14th -16th, 2023.

Opthea to Present at the Jefferies 2023 London Healthcare Conference

MELBOURNE, Australia, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today that Dr. Megan Baldwin, the Company's Founder & Chief Innovation Officer, will present at Eyecelerator which is part of AAO 2023 being held in San Francisco, CA on November 3rd to 6th, 2023.

Opthea to Present at Eyecelerator Forum at the 2023 American Academy of Ophthalmology (AAO) Conference

Dr. Megan Baldwin transitions to Founder, Chief Innovation Officer  and remains on the Board of Directors

Opthea Appoints U.S.-Based Leadership with Fred Guerard as CEO and Peter Lang as CFO

MELBOURNE, Australia, Oct. 02, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today that on October 4th, Dr. Megan Baldwin, the Company's Chief Executive Officer will be a panelist at the inaugural Euretina Innovation Spotlight forum which is part of the Organization's 23rd Congress being held on October 5th – 8th in Amsterdam, The Netherlands.

Opthea to Participate at the 2023 Euretina Congress

MELBOURNE, Australia, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today that Mr. Tim Morris, the Company's Chief Financial Officer will present at H.C. Wainwright's 25th Annual Global Investment Conference being held at the Lotte New York Palace Hotel in New York City on September 11th – 13th, 2023.

Opthea to Present at the H.C. Wainwright 25th Annual Global Investment Conference

MELBOURNE, Australia, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (Opthea or the Company) (ASX:OPT; NASDAQ:OPT) is pleased to announce the successful completion of the institutional component of the capital raising announced on Thursday, 24 August 2023.

Opthea Successfully Completes Institutional Offer and Increases Capital Raising to A$90.0m (US$57.6 million¹)

MELBOURNE, Australia, July 26, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today that the American Medical Association's United States Adopted Names (USAN) Council, in consultation with the World Health Organization's International Nonproprietary Names (INN) Expert Committee, has approved and adopted the nonproprietary drug name “sozinibercept” (pronounced soe'' zi nib' er sept) for the Company's lead biologic drug candidate, OPT-302.

Opthea Announces “Sozinibercept” as the Nonproprietary Drug Name for OPT-302

MELBOURNE, Australia, July 24, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today that Dr. Megan Baldwin, the Company's Chief Executive Officer will present at the 2023 Opthalmology Innovation Summit being held in Seattle, WA on July 27th, 2023.

Opthea to Present at the 2023 Ophthalmology Innovation Summit

MELBOURNE, Australia, July 13, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today that OPT-302, the Company's first-in-class VEGF-C/D “trap” inhibitor will be highlighted during the upcoming American Society of Retina Specialists (ASRS) 2023 Annual Meeting in Seattle, Washington. The ASRS is the largest organization of retina specialists in the world, with more than 3,000 members from 63 countries, and the annual meeting represents one of the largest U.S. conferences covering retinal diseases.

Opthea to Feature at the American Society of Retina Specialists 2023 Annual Meeting

MELBOURNE, Australia, July 10, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today  the  resignation of Dr. Joel Naor, Chief Medical Officer (CMO), effective July 15th, 2023.  Dr. Naor is stepping down to pursue new opportunities and will be replaced by Dr. Kenneth Sall, MD who has been appointed as Opthea's Senior Medical Advisor.  Dr. Sall will assume responsibility for safety oversight of the Opthea's Phase 3 clinical trials investigating OPT-302, a novel VEGF-C/D ‘trap' inhibitor, for the treatment of wet age-related macular degeneration (wet AMD).

Opthea Announces Departure of Chief Medical Officer and Appointment of Senior Medical Advisor

MELBOURNE, Australia, June 08, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, is pleased to announce the appointment of Mr. Anshul Thakral as a Non-Executive Director of the Company's Board of Directors. Concurrently with this appointment, Mr. Michael Sistenich has resigned as a Non-Executive Director, having served for over 7 years on the Board.

Opthea Appoints Anshul Thakral as Non-Executive Director of the Board

MELBOURNE, Australia, May 25, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today that Dr. Megan Baldwin, the Company's Chief Executive Officer will present at the Jefferies Healthcare Conference being held at the Marriott Marquis in New York City on June 7-9 2023.

Opthea to Present at the Jefferies 2023 Healthcare Conference

MELBOURNE, Australia, May 17, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today that Elemer Piros, Senior Biotechnlogy Analyst at EF Hutton will host a webinar with Dr. Megan Baldwin, CEO and Managing Director and Timothy E. Morris, CFO of Opthea Limited on Thursday, May 18th at 5:00 pm EDT (Friday, May 19th at 7:00 am AEST).

Opthea to Participate in EF Hutton Hosted Discussion on OPT-302 and the Wet AMD Market

MELBOURNE, Australia, May 08, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today that Timothy E. Morris, the Company's Chief Financial Officer will present at the JMP Securities Life Sciences Conference being held in New York City on May 15-16 2023.

Opthea To Present at the JMP Securities Life Sciences Conference

MELBOURNE, Australia, April 28, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today that management will participate in the one-on-one meeting portion of the H.C. Wainwright BioConnect Conference being held on May 2, 2023. The Conference is produced in partnership with NASDAQ and will take place at the exchange's world headquarters in New York City (151 West 42nd Street).

Opthea To Participate at the H.C. Wainwright BioConnect Conference at NASDAQ

MELBOURNE, Australia, March 07, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; Nasdaq:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today that it has received an A$8.7 million (US$6.3 million) research and development (R&D) tax credit from the Australian Taxation Office. The cash incentive is for research and development costs incurred in the 2021/2022 financial year, and represents the amount disclosed in the company's audited financial statements at 30 June 2022.

Opthea Receives A$8.7 million R&D Tax Incentive

MELBOURNE, Australia, March 06, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today that Dr. Megan Baldwin, the Company's Chief Executive Officer, will participate in a fireside chat at Oppenheimer's 33rd Annual Healthcare Conference being held virtually on March 13-15, 2023.

News for Opthea Stock (OPT)